EuropeanHIVHep_Emblem
Topics
Meeting category
Date(s)
4 Jun 2025 - 6 Jun 2025
Important dates
Standard Fee Registration Deadline
Friday, 4 April 2025 at 23:59 CEST
Location
Barcelona, Spain
Meeting type
In-Person Meeting
European CME credits (ECMEC®s)
11
Register

23rd European Meeting on HIV & Hepatitis 2025

Register
General
What's New

  • The 23rd European Meeting on HIV & Hepatitis 2025 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 11 European CME credits (ECMEC®s). For more information, please visit the 'Accreditation' tab.

  • The Standard Fee Registration Deadline ends on Friday, 4 April 2025 at 23:59 CEST. Click here for fees and conditions.

  • The Abstract Submission Portal is officially closed. The reviewing process is now in progress. A final outcome is expected to be provided in the week of 24-28 March 2025.

  • Accreditation and Compliant Status has been requested from the following:

    • European Accreditation Council for Continuing Medical Education (EACCME)
    • Ethical MedTech Europe

  • The 23rd European Meeting on HIV & Hepatitis 2025 will be held from 4-6 June 2025 in Barcelona, Spain. For this edition of the meeting, we will be returning to the Hotel Catalonia Barcelona Plaza to host this valuable program. Please find more information regarding the location here below under "Venue".

  • The enduring materials of the previous editions to this meeting are located here.

  • To stay updated on the relevant developments, make sure you are signed up for our newsletter. 

About this Program

It is our pleasure to confirm that the 23rd Edition of the European Meeting on HIV & Hepatitis will take place as a live meeting on 4-6 June 2025 in Barcelona, Spain.

Founded more than twenty years ago as the European HIV Resistance Workshop, the European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance has evolved to embrace all aspects of the clinical care of people living with HIV in Europe. This workshop places emphasis in particular on optimal treatment strategies, clinical virology, molecular epidemiology, and public health aspects of HIV, HBV, HCV, as well as emerging viruses throughout Europe.

In the last decade, the meeting has been able to capture leading clinicians and researchers from different regions of Europe. As such, this meeting is the only European platform where HIV-treating physicians and clinical virologists get together on an annual basis to present their latest research results and discuss their clinical implications in detail.

General Information 
Who Should Attend?
Primary: Europe-based clinicians/physicians and researchers involved in the fields of HIV, HBV, and HCV.

Secondary: Laboratory managers, technicians, pharmacists, and pharmacologists.

- Residents, post-graduates, and PhD students

- Government agency personnel, NGO representatives, and health authority personnel

- Industry representatives

- Social workers, advocates, and community workers

- Other healthcare professionals involved in treating HIV and co-infected patients
Meeting Objectives
This meeting aims to:

- Gather professionals in the fields of HIV and hepatitis clinical care and research in an interactive workshop setting;

- Provide a platform for presentation and discussion of the latest developments in the field of antiviral drug development;

- Map important current studies and results;

- Translate new data into treatment guidelines; and

- Educate clinicians on how to best implement current and new drugs in clinical practice.
Learning Objectives
After participating in this activity, participants will be able to:

- Summarize recent results (including clinical trial results) in drug development for HIV or Hepatitis;

- Apply the latest scientific results into daily clinical care to improve the quality of life of individuals living with HIV; and

- Identify future challenges in the screening, monitoring and diagnosis of patients living with HIV or Hepatitis and develop new concepts for research and care strategies.
Practical Information 
Ethical MedTech
The 23rd European Meeting on HIV & Hepatitis 2025 is currently under review by the Ethical MedTech Europe platform.

For more information, you can visit the website of Ethical MedTech EU with the following link: https://www.ethicalmedtech.eu/
Venue
The confirmed venue for the 23rd European Meeting on HIV & Hepatitis 2025 is at the following location:

Hotel Catalonia Barcelona Plaza
Pl. d'Espanya, 8, Sants-Montjuïc
08014 Barcelona
Spain

Distance from Barcelona Airport (BCN): 13 km
Accommodation
Accommodation is not included in the registration fee.
Badges
All participants are requested to wear the badge at all times during the conference to ensure admission to the meeting.
Certificate of Attendance
A certificate of attendance will be sent to you after successfully completing the program and post-meeting survey.
Language
The official language of the meeting is English

Translation will not be provided.
Meeting Materials
Meeting materials can be obtained upon registration at the registration desk at the Meeting Venue.
Disclaimer
This meeting is intended for educational purposes only and aims to offer participants the opportunity to share information. The Organizing Secretariat of this event, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this meeting. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the conference.
Liability and Insurance
By registering for the meeting participants agree that the organizers do not accept responsibility for medical-, travel- or personal insurance. Participants are advised to take out their own insurance policies.
Photographs, Audio, and Video Recording
Photographs, audio, and video recordings are not permitted at the official meeting sessions. Only the official medical writer appointed by the organization may make recordings. All presentations will be posted here as soon as possible after the workshop is finished, provided the speaker has given permission to do so.
Code of Conduct
All attendees, speakers, co-organizers, partners, endorsers, suppliers, volunteers, and employees at any of our programs are expected to observe our Code of Conduct. We cannot tolerate any form of discrimination, harassment, disrespect, or the marginalization of those involved in our programs. All participants of VE and AME-organized programs are expected to treat others with dignity and respect at all times.

Any individual who feels discriminated against, harassed, disrespected, or marginalized is encouraged to report the incident(s) to VE and AME via info@amededu.com or to one of our on-site personnel.

Any participant who is found to have exhibited any inappropriate conduct or behavior against others may be removed from the program.
Registration

Register with the Early Fee Now!

Register
Fees and Conditions

Registration Fees

Regular Delegates 

Industry Delegates

Early Fee

(payment before/on 3 January 2025)

€595

€1,195

Standard Fee

(payment before/on 4 April 2025)

€745

€1,495

Late Fee

(payment from 5 April 2025)

€845

€1,595

Fee Waivers

Abstract Submitters who are eligible as:

Early-Career Investigators (ECI); OR
"Regular Delegates" from a Resource-Limited Setting (RLS)

50% discount on the Early Fee

Abstract Submitters who are eligible as "Regular delegates" from a High Income Countries

Early applicable fee

Early-Career Investigators (ECI) & "Regular Delegates" from a Resource-Limited Setting (RLS)

50% discount on the current applicable fee

Representatives of Endorsing Organizations 

25% discount on the current applicable fee

Representatives of Sponsoring Industry

Please contact the meeting secretariat

Financial Concerns

If you have financial concerns, please contact the meeting secretariat

*Countries included in the low-income and middle-income economies list of the World Bank Classification

Important

  • We strongly advise that you register early to ensure your registration. Registration will close when the capacity of the venue is reached.

  • Submission of your online registration does not guarantee that your registration has been accepted. Your registration is final when full prepayment has been received and a confirmation of your registration has been sent.

Registration Fee Includes
- Access to all scientific sessions, including poster area;
- Conference pack, including digital abstract book and printed program book;
- Refreshments during the coffee breaks;
- Buffet lunch on meeting days;
- Complimentary entrance to the Networking Reception*
- Access to all enduring materials

* The Networking Reception will take place in the same venue of the meeting and will not have any music / entertainment of any shape or form. The Networking Reception only offers finger foods and the opportunity to have a look at the chosen abstract poster presentations.

IMPORTANT:

- No day rate is available

- The Networking Dinner is not included in the registration fee. Should you wish to attend the Networking Dinner, an additional fee of €65 is charged. Pre-booking is required via the conference secretariat.

- Virology Education reserves the right to cancel improper registrations. Claims for a refund will not be honored.
Group Registration
For registration of groups larger than 5 participants, please contact the meeting secretariat at Michelle.Wu@amededu.com.
Early-Career Investigators / Regular Delegate from Resource-limited Settings (RLS)
To be eligible as an early-career investigator, one should either be:

- A current Master/PhD student; OR
- Have obtained an MD/PharmD/PhD degree in the last five years.

An application form needs to be completed by a supervisor and received by the Virology Education secretariat at least two weeks prior to the start of the workshop. Virology Education will contact the early-career investigator with instructions regarding the registration procedure.

Please find the forms below.
Downloads:
Payment
By credit card only: online or by written authorization (see online registration).

Please contact the Secretariat at Michelle.Wu@amededu.com if you need to make alternative arrangements.
Cancellation Policy
In case of cancellation, the following refunds are applicable:

- Cancellation before/on 4 May 2025: 50% refund (minus an administration fee of €40)

- Cancellation after 4 May 2025: Unfortunately, no refund will be given

If you are unable to attend the conference, a substitute delegate is always welcome at no extra charge, provided that a letter of authorization from the original participant has been received and the conference secretariat has been notified of the name of the substitute delegate before 21 May 2025. A statement (email/letter) of cancellation must be sent to Virology Education.
Liability and Insurance
By registering for the conference, participants agree that the organizers do not accept responsibility for medical, travel, or personal insurance. Participants are advised to take out their own insurance policies.
Media Registration
In order to register as a media participant for the Conference, the conference secretariat needs to receive:

1. Proof of accreditation
2. Valid identification (e.g. passport)
3. A letter from your assignment giver stating the details of your assignment (e.g. editor)
4. At least 3 previous written assignments in recognized outlets on HIV. If you are a freelance journalist, the assignments can be from different (recognizable) news outlets. Links to online publications are accepted
5. The website of the publication(s)/blog(s) that will be featuring your story on this workshop

A complimentary or reduced registration fee may apply for accredited media participants depending on availability. Preference will be given to credible print and online news sources. Please contact the conference secretariat for registration conditions.

We would like to receive a copy of your workshop report/ article once it is finalized.
All credentials will be verified by the Organizing Committee of the Workshop. Media representatives are kindly requested to register by sending the above-mentioned information to info@amededu.com.

Important: Media is restricted to the written press. Recording on film or photo is not allowed. Virology Education will request a copy of the written piece once it is finalized. Media representatives must also agree to abide by the 2020 embargo policy.
Disclaimer
This workshop is intended for educational purposes only and aims to offer participants the opportunity to share information. The organizing secretariat of this workshop, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this workshop. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the workshop. In case of cancellation of the meeting due to unforeseen circumstances, Virology Education cannot be held responsible for expenses made for travel, accommodation, visa applications, etc.
Program

Please find below the Program of the Meeting.

Wednesday, 4 June 2025

Opening of the Meeting - 14:00
14:00 CEST
Opening Words
14:05 CEST
Welcome to Barcelona
Bonaventura Clotet
Bonaventura Clotet, MD, PhD
Universitat Autònoma de Barcelona, Spain
Session 1: Implementation of HIV Prevention in Europe - 14:15
14:15 CEST
Efficacy, Toxicity and Adherence Considerations
Ambrosioni, Juan 2021
Juan Ambrosioni, MD, PhD
University of Barcelona, Spain
14:30 CEST
Logistical / Infrastructure Considerations
Calaf, Àngel Rivero 2025
Àngel Rivero Calaf, MD
Hospital Germans Trias i Pujol, Badalona / BCN CheckPoint / BCN PrEP Point, Spain
14:45 CEST
Price Considerations
Cambiano, Valentina 2025
Valentina Cambiano, PhD
Institute for Global Health, University College London, United Kingdom
15:00 CEST
Panel Discussion: Should Superiority Entail Immediate Implementation?
15:45 CEST
Coffee Break & Poster Viewing
Session 2: Abstract-Driven Session - 16:15
16:15 CEST
Oral Abstract Presentation #1 - Comparable dynamics of cell-associated HIV-RNA, total and intact proviral HIV-1 DNA in virologically suppressed people with HIV switching to 2DR or continuing 3DR over a 18-month follow-up
Lia Fiaschi
University of Siena, Italy
16:25 CEST
Oral Abstract Presentation #2 - In addition to their ability to induce resistance to antiretrovirals, integrase inhibitors and lenacapavir resistance mutations enable HIV-1 to evade recognition by the innate immune system
Elisa Teyssou
Institut Pierre Louis d’Epidémiologie et de Santé Publique Virology Department, France
16:35 CEST
Oral Abstract Presentation #3 - Unveiling novel microbiome signatures for natural virological control in HIV-1 Elite Controllers
Xiangning Bai
Karolinska Institutet, Sweden
16:45 CEST
Oral Abstract Presentation #4 - WG-am: A novel antiviral dipeptide from Elite Controllers as a promising vaginal microbicide for HIV prevention
Rafael Cena Diez
Karolinska Institute, Sweden
16:55 CEST
Discussion
Guided Poster Tour & Networking Reception - 17:15
17:15 CEST
Guided Poster Tour 1
18:10 CEST
Networking Reception

Thursday, 5 June 2025

Session 3: HIV Drug Resistance - 08:30
08:30 CEST
Charles Boucher Lecture: Clinically Relevant Interpretation of Capsid Inhibitor Resistance
Calvez, Vincent 2017
Vincent Calvez, MD, PhD
Pitié-Sapêtrière Hospital, France
08:50 CEST
Update on Resistance to Integrase Inhibitors: Resource Rich versus Resource Limited Settings
Annemarie Wensing
Annemarie Wensing, MD, PhD
University Medical Center Utrecht, the Netherlands
09:10 CEST
Mechanisms of Integrase Inhibitor Drug Resistance
Ravindra Gupta
Ravindra Gupta, MA, MPH, PhD, FRCP, FRCPath, FRSB, FMedSci
University of Cambridge, United Kingdom
09:30 CEST
Oral Abstract Presentation #5 - A French national real-world survey of people with multi-resistant HIV-1 viruses treated with an antiretroviral regimen including fostemsavir or ibalizumab
Charlotte Carpentier
Hôpital Bichat-Claude Bernard - INSERM IAME U1137, France
09:40 CEST
Oral Abstract Presentation #6 - Lenacapavir Resistance Profile in Heavily Treatment-Experienced People in the PRESTIGIO Registry
Maria Mercedes Santoro
University of Rome Tor Vergata, Italy
9:50 CEST
Oral Abstract Presentation #7 - Resistance Analysis of Long-Acting Lenacapavir in Heavily Treatment-Experienced People With HIV After 3 Years of Lenacapavir Treatment
Nicolas Margot
Gilead Sciences Inc., United States
10:00 CEST
Discussion
10:10 CEST
Coffee Break & Poster Viewing
Session 4: Lightning Poster Presentations - Resistance - 10:40
10:40 CEST
Lightning Poster Abstract Presentation #8 - Analysis of 16 Years of ARV Resistance Transmission in Newly Diagnosed HIV Cases in Spain (2007-2023): 2023 Update and the Impact of PrEP on M184V Detection
Paloma Munoz
University Hospital of San Cecilio, Granada, Spain
10:45 CEST
Lightning Poster Abstract Presentation #9 - Clearance of NNRTI resistance-associated mutations in the HIV-1 DNA reservoir with or without the presence of M184V mutation
Anne-Geneviève Marcelin
Sorbonne Université, Inserm, IPLESP, APHP Pitié Salpêtrière, Laboratoire De Virologie, France
10:50 CEST
Lightning Poster Abstract Presentation #10 - Resistance Analyses of F/TAF, F/TDF, and Lenacapavir in the PURPOSE 1 and 2 Studies
Stephanie Cox
Gilead Sciences Inc., United States
10:55 CEST
Discussion
Session 5: Improving the Clinical Utility of HIV / Hepatitis Drug Resistance Assay Results - 11:00
11:00 CEST
How to Improve Fruitful Dialogue between the Virology Lab and Clinicians
Clinician Perspective
Parczewski, Milosz
Miłosz Parczewski, MD, PhD
Pomeranian Medical University, Szczecin, Poland
Lab Manager Perspective
Francesca Ceccherini– Silberstein
Francesca Ceccherini-Silberstein, PhD
University of Rome “Tor Vergata”, Italy
11:30 CEST
Andrea de Luca Lecture: Biomedical Innovations in Drug Resistance Interpretation
Zazzi, Maurizio 2025
Maurizio Zazzi, MSc
University of Siena, Italy
11:45 CEST
Discussion
12:00 CEST
Industry-Supported Symposium - The full program of "Industry-Supported Symposium" can be visited under the "Industry Program" Tab
12:45 CEST
Lunch
Session 6: Lightning Poster Presentations - Resistance - 13:45
13:45 CEST
Lightning Poster Abstract Presentation #11 - Early treatment failure with lenacapavir in HIV-2 infection
Martin Obermeier
MVZ medizinisches Infektiologiezentrum Berlin AG Aufgang A09, Germany
13:50 CEST
Lightning Poster Abstract Presentation #12 - Increased Dynamics of Novel A6/B Recombinant Forms Emergence Following Full-Scale War in Ukraine
Karol Serwin
Department of Infectious, Tropical Diseases And Immune Deficiency Pomeranian Medical University, Szczecin, Poland
13:55 CEST
Lightning Poster Abstract Presentation #13 - Estimating the genetic barrier for resistance to integrase inhibitors for the most frequently circulating HIV-1 subtypes
Mafalda N.S.Miranda
University Medical Center Utrecht, The Netherlands
14:00 CEST
Lightning Poster Abstract Presentation #14 - Three-years outcome after genotyping-guided switch in HIV multidrug resistant patients in Cameroon: Evidence-based strategies for achieving epidemic control in low-and middle-income countries
Ezechiel Ngoufack Jagni Semengue
Centre International De Référence Chantal Biya, Cameroon
14:05 CEST
Lightning Poster Abstract Presentation #15 - Virologic failure and resistance emergence during treatment with B/F/TAF or DTG/3TC in PWH without prior resistance mutations: a real-world study
Thomas Drumel
Chu Nantes, France
14:10 CEST
Discussion
14:15 CEST
Industry-Supported Symposium - The full program of "Industry-Supported Symposium" can be visited under the "Industry Program" Tab
15:00 CEST
Coffee Break & Poster Viewing
Session 7: Development of Viral Variants - 15:30
15:30 CEST
Restrictions and Drivers for the Development of (HIV) Variants
Prof. Dr. Roger Kouyos
University Hospital Zurich, Switzerland
15:50 CEST
Oral Abstract Presentation #16 - APOBEC-Associated Mutations in HIV Drug Resistance: Challenges in Interpretation Using Next-Generation Sequencing
Paloma Munoz
University Hospital of San Cecilio, Granada, Spain
16:00 CEST
Oral Abstract Presentation #17 - Clonal analysis of near full-length proviral HIV-1 genome enables differentiation of APOBEC- and drug-resistant populations in highly treatment experienced people living with HIV
Martin Daeumer
Institute of Immunology and Genetics, Germany
16:10 CEST
Discussion
Session 8: Viral Hepatitis - Elimination Strategies - 16:20
16:20 CEST
HCV Elimination - Why Do We Still Have Gaps and How to Close this Gaps?
Pavel Khaykin, MD
Pavel Khaykin, MD
MainFachArzt Frankfurt, Germany
16:40 CEST
Micro-Elimination Approaches - IV Drug Users
Manolakopoulos, Spilios 2025.
Spilios Manolakopoulos, MD
National and Kapodistrian University of Athens / Hippokration General Hospital, Greece
17:00 CEST
Oral Abstract Presentation #18 - Progress and Challenges in Hepatitis B and C Elimination Efforts Across Europe: A Comprehensive Analysis
Geoffrey Ogbeke
National Aids, Viral Hepatitis & Stis Control Programme, Nigeria
17:10 CEST
Oral Abstract Presentation #19 - Despite a substantial burden of HDV infection, gaps in HDV screening still persists across Europe: an urgent need to strengthen diagnostic strategies at pan-European level
Ilaria Grossi
University of Rome Tor Vergata Department of Biology, Italy
17:20 CEST
Oral Abstract Presentation #20 - Boosting HDV Testing in Spain through the Delta Double Reflex Strategy
Marta Illescas Lopez
Hospital Universitario Clínico San Cecilio, Spain
17:30 CEST
Oral Abstract Presentation #21 - Viral strain networks tracing human or environment-linked Hepatitis E Virus dispersion in Europe - HEV molecular signatures
Evelyne Schvoerer
Virologie CHU et Université de Lorraine (UL), France
17:40 CEST
Discussion
Guided Poster Tour & Networking Dinner - 18:00
18:00 CEST
Guided Poster Tour 2
20:00 CEST
Networking Dinner

Friday, 6 June 2025

Session 9: Viral Hepatitis - HBV / HDV - 09:00
09:00 CEST
Risk for Re-Activation in HIV Coinfected Individuals with Dual Regimens Without TDF/TAF
Geretti, Anna Maria
Anna Maria Geretti, MD, PhD, FRCPath
University of Rome, Italy / King's College London, United Kingdom
09:20 CEST
Update Novel Biomarkers and Compounds in HBV / HDV
Svicher, Valentina
Valentina Svicher, PhD
University of Rome “Tor Vergata”, Italy
09:40 CEST
Oral Abstract Presentation #22 - Chronic HDV coinfection is characterized by a more elevated production of all three HBsAg isoforms compared to HBV mono-infection, that parallels HDV replicative and cytolytic activity
Stefano D'Anna
Department of Biology, University of Rome Tor Vergata, Italy
09:50 CEST
Oral Abstract Presentation #23 - A high degree of genetic variability characterises HDV sub-genotypes 1 and can drive the selection of divergent genetic pathways modulating HDV replicative potential and cytolytic activity
Lorenzo Piermatteo
University of Rome "Tor Vergata", Italy
10:00 CEST
Oral Abstract Presentation #24 - HDV Molecular Epidemiology in Spain: Insights from Whole-Genome Sequencing
Marta Illescas Lopez
Hospital Universitario Clínico San Cecilio, Spain
10:10 CEST
Oral Abstract Presentation #25 - Implementation of a multicenter reflex testing program for hepatitis D detection of and registration of positive cases in Catalonia
Adriana Palom
Liver Unit, Hospital Unversitari Vall D'Hebron, Spain
10:20 CEST
Discussion
10:30 CEST
Coffee Break & Poster Viewing
Session 10: Abstract-Driven Session - SARS-CoV-2 - 11:00
11:00 CEST
Oral Abstract Presentation #26 - Global burden of SARS-CoV-2 infection, hospitalization and case fatality rate among COVID-19 vaccinated individuals and its associated factors: a systematic review and meta-analysis
Aurelie Minelle Kengni Ngueko
Chantal Biya International Reference Center For Research on HIV Prevention and Management (CIRCB)), Cameroon
11:10 CEST
Oral Abstract Presentation #27 - Intra-host evolution of SARS-CoV-2 during prolonged infection
Alessia Lai
University of Milan, Italy
11:20 CEST
Oral Abstract Presentation #28 - Early Detection of SARS-CoV-2 Variants in a School Cohort Using Next-Generation Sequencing: Insights from the EUCARE Project
André Santos
Universidade NOVA de Lisboa, Portugal
11:30 CEST
Oral Abstract Presentation #29 - Evaluation of the SARS-CoV-2 virus genetic barrier to Remdesivir and Nirmatrelvir in vitro and in vivo
Ilenia Varasi
Department of Medical Biotechnologies, University of Siena, Siena, Italy
11:40 CEST
Discussion
Session 11: What’s in the Pipeline? Presentations on Future Viral Therapeutics and Vaccines from Scientists from Industry -
The full program of "Session 11" can be visited under the "Industry Program" Tab
13:00 CEST
Lunch
Session 12: Hot Topics - 14:00
14:00 CEST
Transmission Networks - Translation in Public Health Policies
Paraskevis, Dimitrios
Dimitrios Paraskevis, PhD
National and Kapodistrian University of Athens, Greece
14:20 CEST
Baseline Resistance Testing - Do We Still Need It?
Garcia, Federico 2024
Federico García, PharmD, PhD
Hospital Universitario San Cecilio, Spain
14:40 CEST
Discussion
15:00 CEST
Notes from EACS - President
Parczewski, Milosz
Miłosz Parczewski, MD, PhD
Pomeranian Medical University, Szczecin, Poland
15:15 CEST
Closure of the Meeting and Ricardo Camacho Awards
15:30 CEST
End of the Meeting
Industry Program
Please find below the program of the Industry Sessions that are part of the Meeting

Friday, 6 June 2025 

Session 11: What’s in the Pipeline? Presentations on Future Viral Therapeutics and Vaccines from Scientists from Industry (non-CME)
- 11:50
11:50 CEST
Gilead Sciences
Cohen, Cal_2023_2
Calvin Cohen, MD, MSc
Executive Director, Global HIV Medical Affairs, Gilead Sciences, United States
12:10 CEST
ViiV Healthcare
Garges, Harmony
Harmony Garges, MD, MPH
Senior Vice President, Chief Medical Officer and Head of Global Medical, ViiV Healthcare, United States
12:30 CEST
Update on the MSD HIV Pipeline: Prevention, Treatment, and Cure
Photo_Campo, Rafael 2_2022
Rafael E. Campo, MD
Executive Director, Global HIV Scientific Affairs, MSD, United States
12:50 CEST
Discussion
13:00 CEST
Lunch
Abstracts

Abstract Portal Closed!

Abstracts
  • The Abstract Submission Portal is officially closed. The reviewing process is now in progress. A final outcome is expected to be provided in the week of 24-28 March 2025.
     
  • The European Meeting on HIV & Hepatitis 2025 accepts new original data as well as encored abstracts. All abstracts must focus on the European region and contain up-to-date information at the time of the meeting.
     
  • Early-Career Investigators (ECI) or "Regular Delegate" from Resource-Limited Setting (RLS) with an accepted abstract are able to receive a 50% discount off of the early registration fee. The requirements for the application are specified here.

  • Abstract submitters are strongly encouraged to use person-first language in their abstracts. View the video tutorial and guidelines here

  • Abstract presenters are expected to attend the meeting in-person to present their abstract. Please contact the meeting secretariat if this is not possible.

Image
meeting 1
Categories for Abstract Submission
For purposes of review and programming, abstracts are divided into topical categories. The selection of the most appropriate category is important as it determines who reviews your abstract. The Reviewing Committee reserves the right to reassign your abstract to a more appropriate category. Click here for an overview of the categories.

Abstract Categories:

• Clinical Cases
• Viral Evolution and Genetic Diversity
• Novel Diagnostic Technologies and Approaches
• HIV Prevention, Strategies, and Implementation
• Treatment Options - HIV
• Treatment Options - Viral Hepatitis
• Clinical Implications of Antiviral Drug Resistance
• Interpretation of Antiviral Drug Resistance
• Spread of Drug Resistance
• Therapeutic Challenges in Resource-Limited Settings
• Management of COVID-19 and Other Respiratory Viruses
• Clinical Research on HIV and/or Viral Hepatitis
• HIV Inflammation and Cure
General Guidelines
Abstracts should contain the following four components:

- Background: A concise statement of the issue under investigation or a hypothesis;

- Material and Methods: The experimental methods used (including the statistical analyses employed);

- Results: Specific findings (promises such as "to be completed" or "to be presented" are not acceptable);

- Conclusions: A summary of findings that are supported by your results (statistical analyses used to support the conclusions, where appropriate, should be included; concluding statements such as "the results will be discussed" are not acceptable).

Please note that abstracts cannot be accepted if tables or graphs are included. The maximum word count for the abstract body is 500 words.

Abstracts are considered official communications to the conference and will be treated confidentially. Submitters of accepted abstracts agree to attend the meeting and present their abstract as scheduled.

We encourage you to use person-first language in your abstract(s). View our guidelines here: https://academicmedicaleducation.com/person-first-language
Abstract Submission
Authors can submit their abstracts electronically until the deadline. You will be redirected to the submission website. Please follow the step-by-step directions to upload the abstract. To ensure your abstract retains any special characters or formatting, the abstract must be in Microsoft Word format.
Poster Presentation Instructions
Note: Poster presenters are expected to attend onsite.

Posters need to meet the following requirements:

- Print Size: A0 size (approx. 33" x 47"), printed in portrait format.

- Please display the number of your poster in the upper right corner of your poster.

- Please refrain from printing your poster on textile/fabric, as it will not be able to stick well to the poster boards.

- Please hang your posters as early as possible. All posters must be displayed from the opening session to the closure of the meeting.

- Pushpins and/or tape will be provided.

Once onsite:

Poster presenters are requested to stand near their poster(s) during the poster session.
Committees
Organizing Committee

The members of the Organizing Committee are a group of carefully selected experts and inspirational leaders in their respective fields. They meet frequently to discuss the scientific program of the workshop, identify interesting topics and candidate speakers, and review all submitted abstracts.

Scientific Program Coordinator
Scientific Committee
Abecasis, Ana 2025
Ana B. Abecasis, MD, PhD, PharmD
Global Health and Tropical Medicine (GHTM), Associate Laboratory in Translation and Innovation Towards Global Health (LA-REAL), Instituto de Higiene e Medicina Tropical (IHMT), Universidade NOVA de Lisboa (UNL), Lisboa, Portugal
Nijhuis, Monique
Monique Nijhuis, PhD
University Medical Centre Utrecht, the Netherlands
Obermeier, Martin 2025
Martin Obermeier, MD
German Heart Centre Berlin (DHZB) / Medical Centre for Infectious Diseases in Berlin MVZ mib AG, Germany
No Photo_Faculty
David van de Vijver, PharmD, PhD
Erasmus University Rotterdam, the Netherlands

The members of Scientific Committee are hand-picked by the Organizing Committee and the conference secretariat based on their significant contributions and commitment to the field. They assist the Organizing Committee by providing them with suggestions for speakers and topics. In addition, members of the Scientific Committee participate in reviewing submitted abstracts, and play an active role during the workshop as moderators and/or chairs of sessions.

Support
Gold Level Support

Support provided by ViiV Healthcare

Silver Level Support

Supported by Gilead who provided funding.
Gilead has had no input into the content
of the materials used at this meeting.

Support Our Initiative

Financial backing to the European Meeting on HIV & Hepatitis 2025 helps us deliver an impactful meeting experience to the benefit of healthcare professionals and researchers interested in HIV & Hepatitis in the European region.
 
This collaboration plays a vital role in both the organizational as well as scientific success of the program.

To show your commitment to the cause, get in touch with us for a tailored support package by contacting Jesper Niesen at Jesper.Niesen@amededu.com or call +31 30 230 7140.
 
Benefits of Support
By supporting this program, we can offer the following advantages for your company.* Please contact us for the most recent support level benefits for this program.

  • Symposium opportunities
  • Non-commercial interviews with company representatives
  • Verbal acknowledgement during the program 
  • Discounted and complimentary registrations for your representatives
  • Company acknowledgement on digital meeting materials including but not limited to newsletters, flyers, the streaming platform, and our website
  • Company acknowledgement on printed meeting materials including but not limited to banners and the program book
  • Digital and printed advertising opportunities 
  • Social media shout-outs
  • Logo on the conference bag 

 
*Subject to the support level.

Endorsers

The 23rd European Meeting on HIV & Hepatitis 2025 is endorsed by societies and organizations. Their support and collaboration are key to the success of this workshop. 

If you would like your organization to endorse this meeting, please contact Michelle Wu at Michelle.Wu@amededu.com for more information.

Endorsing Societies and Organizations
Accreditation
EACCME® Accreditation Statement

The European Meeting on HIV & Hepatitis 2025, Barcelona, Spain, 04/06/2025 - 06/06/2025, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 11.0 European CME credits (ECMEC®s). Each medical specialist should claim only those credits that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at https://edhub.ama-assn.org/pages/applications.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Media
Welcome Message 2024

Join us in reliving the highlights of our past event as we look forward to welcoming you to the upcoming European Meeting on HIV & Hepatitis 2025!

Previous Editions
Previous Editions
Language
Related Programs
Afbeelding
Michelle 2022
Caption
Hi! I’m Michelle
Label / Name
How can I help you?
Go to Contact form webform